Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 12Sarcoma 10Genitourinary 9Thoracic 8Gastrointestinal 6CNS 5Breast 4Other solid neoplasm 2Other hematologic neoplasm 2Dermatologic 2Tumor-Agnostic 1Lymphoid 1Head & Neck 1

Conditions

Uveal Melanoma 2Neoplasm Metastasis 1Melanoma 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × cediranib × Dermatologic × Clear all
NCT04184518 2020-06-02

CEDUVEAL-M

Grupo Español Multidisciplinar de Melanoma

Phase 2 Withdrawn
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT00243061 2018-08-27

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
24 enrolled 12 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡